UPDATE 1-Cephalon gets subpoena from U.S. DOJ
September 30, 2011
category
companyNews
EU mergers and takeovers (Sept 28)
September 28, 2011
BRUSSELS, Sept 28 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: Read More
category
companyNews
REFILE-UPDATE 1-Valeant offers C$88 mln for Afexa, tops Paladin
September 26, 2011
category
companyNews
Valeant to offer C$88 mln for Afexa, tops Paladin
September 26, 2011
category
companyNews
EU mergers and takeovers (Sept 23)
September 23, 2011
BRUSSELS, Sept 23 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: Read More
category
companyNews
Teva offers EU watchdog concessions for Cephalon buy
September 23, 2011
BRUSSELS, Sept 23 (Reuters) - Teva Pharmaceutical Industries Ltd has offered concessions in a bid to ease EU regulatory concerns over its plan to buy U.S. speciality drugmaker Cephalon Inc. , the... Read More
category
companyNews
Cephalon sues Sandoz over Fentora cancer drug
September 16, 2011
Sept 16 (Reuters) - Cephalon Inc on Friday sued Novartis AG's Sandoz drug unit, accusing it of trying to infringe two patents related to its Fentora drug that treats pain in adults who have cancer. Read More
category
companyNews
EU mergers and takeovers (Sept 16)
September 16, 2011
BRUSSELS, Sept 16 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: Read More
category
companyNews
EU mergers and takeovers (Sept 14)
September 14, 2011
BRUSSELS, Sept 14 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: Read More
category
companyNews
UPDATE 2-Valeant tops Paladin with C$76 mln bid for Afexa
August 30, 2011
category
companyNews
EU mergers and takeovers (Aug 29)
August 29, 2011
BRUSSELS, Aug 29 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: Read More
category
companyNews
UPDATE 3-Generic threat to Valeant drug sends shares reeling
August 04, 2011
category
companyNews
UPDATE 1-Cephalon quarterly profit falls short of estimates
August 02, 2011
LOS ANGELES, Aug 2 (Reuters) - Drugmaker Cephalon Inc , which is being acquired by Teva Pharmaceutical Industries Ltd , reported lower-than-expected quarterly earnings as revenue fell short of Wall... Read More
category
companyNews
UPDATE 5-Meda shares jump on Valeant bid speculation
July 27, 2011
category
companyNews
UPDATE 3-Valeant makes approach for drugmaker Meda
July 26, 2011
category
companyNews
U.S. stock index futures signal early bounce
June 14, 2011
* U.S. stock index futures pointed to a bounce at the open on Wall Street on Tuesday, with futures for the S&P 500 up 0.9 percent, Dow Jones futures up 0.5 percent and Nasdaq 100 futures up 0.7 percent... Read More
category
companyNews
LOS ANGELES, June 13 (Reuters) - The U.S. Federal Trade Commission has requested additional information on Israel-based Teva Pharmaceutical Industries Ltd's planned acquisition of U.S. drugmaker... Read More
category
companyNews
category
companyNews
UPDATE 2-Teva Q1 profit up on higher European sales
May 11, 2011
category
companyNews
category
companyNews
RPT-DEALTALK-CEOs bare teeth and go hostile
May 03, 2011
* Aggressive approach has varying level of success (For more Reuters DEALTALKs, click DEALTALK/) Read More
category
companyNews
PRESS DIGEST - Financial Times - May 3
May 02, 2011
The killing of Osama bin Laden triggered jubilation among the U.S. population but prompted warnings about possible retaliation attacks by extremist supporters.... Read More
category
companyNews
DEALTALK-CEOs bare teeth and go hostile
May 02, 2011
* Aggressive approach has varying level of success (For more Reuters DEALTALKs, click DEALTALK/) Read More
category
companyNews
category
companyNews
category
companyNews
UPDATE 1-Teva to acquire Cephalon, topping Valeant
May 02, 2011
NEW YORK, May 2 (Reuters) - Teva Pharmaceutical Industries Ltd plans to acquire specialty drugmaker Cephalon for $81.50 a share, topping an unsolicited bid by Canada's Valeant Pharmaceuticals... Read More
category
companyNews
UPDATE 1-Glass Lewis argues against Cephalon board change
April 29, 2011
TORONTO, April 29 (Reuters) - Proxy advisory firm Glass Lewis recommended on Friday that Cephalon shareholders oppose an attempt by Valeant Pharmaceuticals to replace the U.S. drugmaker's board of... Read More
category
companyNews
TORONTO, April 18 (Reuters) - Valeant Pharmaceuticals said on Monday that it had added Abe Friedman, a former global head of corporate governance at BlackRock Inc , to a proposed slate of directors to... Read More
category
companyNews
REFILE-UPDATE 2-Synthes confirms in deal talks with J&J
April 18, 2011
category
companyNews
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here